Published • loading... • Updated
Penetrium Bio launches trial combining new cancer drug with Merck’s Keytruda
Summary by News Article Insiders
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Penetrium Bio launches trial combining new cancer drug with Merck’s Keytruda
Pictured above is the logo of Penetrium Bioscience. [Photo courtesy of Penetrium Bioscience] South Korea’s Penetrium Bioscience announced on June 17 that it has launched a Phase 1 clinical trial combining its investigational cancer drug Penetrium with Merck’s blockbuster immunotherapy Keytruda. The company said that the trial will enroll patients with non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC) who have failed pre…
Father's Day SaleGet 40% off Vantage subscriptions for yourself or a friend.Get Started
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
